SJ0043eng 101ST GENERAL ASSEMBLY

10100SJ0043 Engrossed LRB101 11737 MST 58399 r

SENATE JOINT RESOLUTION NO. 43

(As Amended by Senate Amendment No. 1)

WHEREAS, The human papillomavirus (HPV) is the most common sexually transmitted virus in the United States; nearly 14 million people become infected each year; and

WHEREAS, HPV causes approximately 33,700 cases of HPV-associated cancers each year, including cervical, anal, and oropharyngeal cancers; and

WHEREAS, 9-valent HPV vaccine protects against nine types of HPV infection; and

WHEREAS, The HPV vaccine was tested before being licensed by the Food and Drug Administration and continues to be monitored by the Centers for Disease Control and Prevention and the Food and Drug Administration; and

WHEREAS, The most common side effects are mild and include pain, redness, or swelling in the arm where the shot is given; dizziness, fainting, nausea, and headaches can also occur; and

WHEREAS, The American Academy of Pediatrics (AAP) and the Advisory Committee on Immunization Practices (ACIP) recommend two doses of HPV vaccine for males and females ages 11-12; the vaccine is approved for men and women through age 45; and

WHEREAS, In Illinois, only 50 percent of males and females ages 13-17 years were up to date on HPV vaccination in 2017; therefore, be it

RESOLVED, BY THE SENATE OF THE ONE HUNDRED FIRST GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES CONCURRING HEREIN, that we encourage adolescents in Illinois to receive the HPV vaccine to protect themselves against HPV infection and HPV-related cancers.